1Department of Neurology, Chonnam National University Hospital, Gwangju, Korea
2Department of Nursing, Chonnam National University Hospital, Gwangju, Korea
3Department of Neurology, Chonnam National University Medical School, Gwangju, Korea
© 2026 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
FUNDING
This study was supported by a grant (BCRI25031) of Chonnam National University Hospital Biomedical Research Institute.
ACKNOWLEDGMENTS
None.
AUTHOR CONTRIBUTIONS
Conceptualization: BSS, HH, JJ, HK. Methodology: BSS, HK. Formal analysis: HH, HK. Data curation: BSS, HH, JHH, HK. Project administration: HK. Funding acquisition: HK. Writing - original draft: BSS, HH, HK. Writing - review & editing: HK. All authors read and agreed to the published version of the manuscript.
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
HTS: hypertonic saline; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment; LAA: large artery atherosclerosis; CE: cardioembolism; OD: other determined etiology; UD: undetermined etiology; WBC: white blood cell; BUN: blood urea nitrogen; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated hemoglobin; BP: blood pressure.
Student t-test was used for continuous variables. Fisher's exact test with Monte Carlo simulation was used for categorical variables.
| No. of events/event rate, % (95% CI) | P-valuea) | |||
|---|---|---|---|---|
| All (n=200) | HTS (n=67) | No HTS (n=133) | ||
| Primary outcome | ||||
| Phlebitis | ||||
| All grade | 42/21.0 (15.6–27.3) | 21/31.3 (20.6–43.8) | 21/15.8 (10.1–23.1) | 0.016 |
| Grade 1 | 38/19.0 (13.8–25.1) | 17/25.4 (15.5–37.5) | 21/15.8 (10.0–23.1) | 0.127 |
| Grade 2 | 4/2.0 (0.5–5.0) | 4/6.0 (1.7–14.6) | 0/0.0 (0.0–2.7) | 0.012 |
| Grade 3–4 | - | - | - | |
| Secondary outcome | ||||
| In-hospital mortality | 36/18.0 (12.9–24.0) | 16/23.9 (14.3–35.9) | 20/15.0 (9.4–22.3) | 0.171 |
| 3-Month mRS 0–3 | 48/24.0 (18.3–30.5) | 14/20.9 (11.9–32.6) | 34/25.6 (18.4–33.9) | 0.490 |
| LOS (day) | 9.5 (5.4–15.4) | 10.9 (4.6–18.6) | 9.1 (5.5–13.7) | 0.341 |
Values are presented as number (%, 95% CI by exact binomial method) or median (IQR). Log-rank test was used for mortality (follow-up, 91 days).
HTS: hypertonic saline; mRS: modified Rankin Scale; LOS: hospital length of stay; IQR: interquartile range.
a)Chi-square test for phlebitis; Fisher’s exact test for 3-month mRS 0-3; Mann-Whitney U-test for LOS; Log-rank test for in-hospital mortality.
| Outcome | Statistical model | Crude effect (95% CI) | P-value | Adjusted effect (95% CI) | P-value |
|---|---|---|---|---|---|
| Phlebitis | Logistic regression (OR) | 2.43 (1.21 to 4.91) | 0.012 | 2.19 (1.02 to 4.70) | 0.044 |
| Mortality | Cox proportional hazards (HR) | 1.65 (0.86 to 3.19) | 0.134 | 1.48 (0.73 to 2.97) | 0.274 |
| LOS | Linear regression (β)a) | 0.028 (−0.238 to 0.295) | 0.834 | 0.024 (−0.262 to 0.311) | 0.867 |
Reference group: no-HTS. Adjusted for age, initial National Institutes of Health Stroke Scale score, pre-stroke modified Rankin Scale score, previous antiplatelet treatment, reperfusion therapy, and TOAST classification.
OR: odds ratio; HR: hazard ratio; LOS: hospital length of stay; TOAST: Trial of Org 10172 in Acute Stroke Treatment.
a)Length of stay was log-transformed prior to analysis; β represents the difference in log-transformed days between groups.
Crude odds ratios were estimated using logistic regression with no-HTS as the reference group. Adjusted odds ratios were derived from multivariable logistic regression adjusting for age, initial NIHSS score, pre-stroke modified Rankin Scale score, previous antiplatelet treatment, reperfusion therapy (none/IVT/EVT/IVT+EVT), and TOAST classification. The crude P for trend was calculated using the Cochran-Armitage trend test. The adjusted P for trend was obtained by including HTS frequency as an ordinal variable (0, 1, 2, ≥3) in the multivariable logistic regression model.
OR: odds ratio; HTS: hypertonic saline; NIHSS: National Institutes of Health Stroke Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment.
Multivariable logistic regression model with phlebitis as the dependent variable. All listed covariates were entered simultaneously. Hypertonic saline use was the primary exposure variable.
OR: odds ratio; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment.
| Variable | All (n=200) | No HTS (n=133) | HTS (n=67) | P-value |
|---|---|---|---|---|
| Age (yr) | 75±11 | 76±11 | 73±12 | 0.140 |
| Male | 88 (44.0) | 56 (42.1) | 32 (47.8) | 0.455 |
| Initial NIHSS score | 13.0 (9.0–17.0) | 13.0 (8.0–17.0) | 14.0 (10.0–18.0) | 0.022 |
| Pre-stroke mRS | 0.666 | |||
| mRS 0–1 | 194 (97.0) | 128 (96.2) | 66 (98.5) | |
| mRS 2–5 | 6 (3.0) | 5 (3.8) | 1 (1.5) | |
| Reperfusion therapy | 0.289 | |||
| None | 122 (61.0) | 87 (65.4) | 35 (52.2) | |
| IVT | 32 (16.0) | 18 (13.5) | 14 (20.9) | |
| EVT | 30 (15.0) | 19 (14.3) | 11 (16.4) | |
| IVT+EVT | 16 (8.0) | 9 (6.8) | 7 (10.4) | |
| TOAST classification | 0.790 | |||
| LAA | 31 (15.5) | 21 (15.8) | 10 (14.9) | |
| CE | 94 (47.0) | 64 (48.1) | 30 (44.8) | |
| OD | 2 (1.0) | 2 (1.5) | 0 | |
| UD | 73 (36.5) | 46 (34.6) | 27 (40.3) | |
| Vascular risk factor | ||||
| Prior stroke | 23 (11.5) | 15 (11.3) | 8 (11.9) | >0.999 |
| Coronary heart disease | 21 (10.5) | 17 (12.8) | 4 (6.0) | 0.220 |
| Peripheral artery disease | 3 (1.5) | 2 (1.5) | 1 (1.5) | >0.999 |
| Hypertension | 123 (61.5) | 86 (64.7) | 37 (55.2) | 0.220 |
| Diabetes mellitus | 60 (30.0) | 44 (33.1) | 16 (23.9) | 0.195 |
| Hyperlipidemia | 37 (18.5) | 21 (15.8) | 16 (23.9) | 0.180 |
| Atrial fibrillation | 92 (46.0) | 62 (46.6) | 30 (44.8) | 0.881 |
| Smoking | 0.812 | |||
| Never | 175 (87.5) | 115 (86.5) | 60 (89.6) | |
| Ex-smoker | 19 (9.5) | 13 (9.8) | 6 (9.0) | |
| Current | 6 (3.0) | 5 (3.8) | 1 (1.5) | |
| Medication history | ||||
| Antiplatelet use | 34 (17.0) | 17 (12.8) | 17 (25.4) | 0.030 |
| Anticoagulant use | 37 (18.5) | 25 (18.8) | 12 (17.9) | >0.999 |
| Antihypertensive use | 86 (43.0) | 55 (41.4) | 31 (46.3) | 0.547 |
| Antidiabetic use | 34 (17.0) | 22 (16.5) | 12 (17.9) | 0.843 |
| Statin use | 29 (14.5) | 20 (15.0) | 9 (13.4) | 0.834 |
| Laboratory findings | ||||
| WBC (×10³/µl) | 9.6±3.7 | 9.7±3.4 | 9.4±4.1 | 0.592 |
| Hemoglobin (g/dl) | 13.2±2.1 | 13.3±2.2 | 13.0±1.9 | 0.446 |
| Platelet (×10³/µl) | 218.8±84.1 | 215.2±79.4 | 225.8±92.9 | 0.428 |
| BUN (mg/dl) | 19.4±11.2 | 20.1±12.0 | 18.0±9.4 | 0.179 |
| Creatinine (mg/dl) | 0.8±0.4 | 0.8±0.5 | 0.8±0.2 | 0.672 |
| LDL-C (mg/dl) | 99.7±36.4 | 101.7±36.2 | 95.5±36.9 | 0.259 |
| HDL-C (mg/dl) | 45.0±11.4 | 45.3±11.5 | 44.4±11.4 | 0.612 |
| Total cholesterol (mg/dl) | 166.5±40.5 | 168.8±40.6 | 162.1±40.2 | 0.270 |
| Triglyceride (mg/dl) | 103.1±55.4 | 104.1±52.0 | 101.3±62.0 | 0.752 |
| HbA1c (%) | 6.0±1.0 | 6.0±1.0 | 6.1±1.0 | 0.452 |
| Fasting glucose (mg/dl) | 144.2±47.6 | 144.3±48.2 | 144.0±46.6 | 0.965 |
| Systolic BP (mm Hg) | 142.0±26.0 | 142.0±25.2 | 141.9±27.8 | 0.981 |
| No. of events/event rate, % (95% CI) | P-value |
|||
|---|---|---|---|---|
| All (n=200) | HTS (n=67) | No HTS (n=133) | ||
| Primary outcome | ||||
| Phlebitis | ||||
| All grade | 42/21.0 (15.6–27.3) | 21/31.3 (20.6–43.8) | 21/15.8 (10.1–23.1) | 0.016 |
| Grade 1 | 38/19.0 (13.8–25.1) | 17/25.4 (15.5–37.5) | 21/15.8 (10.0–23.1) | 0.127 |
| Grade 2 | 4/2.0 (0.5–5.0) | 4/6.0 (1.7–14.6) | 0/0.0 (0.0–2.7) | 0.012 |
| Grade 3–4 | - | - | - | |
| Secondary outcome | ||||
| In-hospital mortality | 36/18.0 (12.9–24.0) | 16/23.9 (14.3–35.9) | 20/15.0 (9.4–22.3) | 0.171 |
| 3-Month mRS 0–3 | 48/24.0 (18.3–30.5) | 14/20.9 (11.9–32.6) | 34/25.6 (18.4–33.9) | 0.490 |
| LOS (day) | 9.5 (5.4–15.4) | 10.9 (4.6–18.6) | 9.1 (5.5–13.7) | 0.341 |
| Outcome | Statistical model | Crude effect (95% CI) | P-value | Adjusted effect (95% CI) | P-value |
|---|---|---|---|---|---|
| Phlebitis | Logistic regression (OR) | 2.43 (1.21 to 4.91) | 0.012 | 2.19 (1.02 to 4.70) | 0.044 |
| Mortality | Cox proportional hazards (HR) | 1.65 (0.86 to 3.19) | 0.134 | 1.48 (0.73 to 2.97) | 0.274 |
| LOS | Linear regression (β |
0.028 (−0.238 to 0.295) | 0.834 | 0.024 (−0.262 to 0.311) | 0.867 |
| Group | Number | Phlebitis n (%, 95% CI) | Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
|---|---|---|---|---|---|---|
| HTS (−) | 133 | 21 (15.8, 10.0–23.1) | 1.00 (reference) | 1.00 (reference) | ||
| HTS (+) 1 | 30 | 3 (10.0, 2.1–26.5) | 0.59 (0.13–1.88) | 0.423 | 0.51 (0.11–1.75) | 0.325 |
| HTS (+) 2 | 15 | 8 (53.3, 26.6–78.7) | 6.10 (1.99–19.19) | 0.002 | 5.43 (1.65–18.22) | 0.005 |
| HTS (+) ≥3 | 22 | 10 (45.5, 24.4–67.8) | 4.44 (1.68–11.68) | 0.002 | 3.59 (1.25–10.27) | 0.016 |
| P for trend | <0.001 | 0.002 |
| Variable | Adjusted OR (95% CI) | P-value |
|---|---|---|
| Hypertonic saline use | 2.21 (1.03–4.75) | 0.040 |
| Age (per 1-year increase) | 0.99 (0.95–1.03) | 0.529 |
| Male sex | 1.16 (0.53–2.53) | 0.709 |
| Initial NIHSS (per 1-point increase) | 1.04 (0.98–1.10) | 0.225 |
| Pre-stroke mRS (per 1-point increase) | 1.11 (0.49–2.07) | 0.764 |
| Reperfusion: IVT (vs. none) | 2.11 (0.79–5.45) | 0.127 |
| Reperfusion: EVT (vs. none) | 1.06 (0.35–2.99) | 0.909 |
| Reperfusion: IVT+EVT (vs. none) | 1.00 (0.23–3.57) | 0.996 |
| TOAST: cardioembolism | 0.30 (0.07–1.16) | 0.086 |
| Prior antiplatelet use | 0.51 (0.15–1.40) | 0.222 |
| Hypertension | 0.89 (0.40–2.00) | 0.772 |
| Diabetes mellitus | 0.94 (0.39–2.22) | 0.895 |
| Atrial fibrillation | 2.18 (0.57–8.82) | 0.258 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). HTS: hypertonic saline; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment; LAA: large artery atherosclerosis; CE: cardioembolism; OD: other determined etiology; UD: undetermined etiology; WBC: white blood cell; BUN: blood urea nitrogen; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated hemoglobin; BP: blood pressure. Student t-test was used for continuous variables. Fisher's exact test with Monte Carlo simulation was used for categorical variables.
Values are presented as number (%, 95% CI by exact binomial method) or median (IQR). Log-rank test was used for mortality (follow-up, 91 days). HTS: hypertonic saline; mRS: modified Rankin Scale; LOS: hospital length of stay; IQR: interquartile range. Chi-square test for phlebitis; Fisher’s exact test for 3-month mRS 0-3; Mann-Whitney U-test for LOS; Log-rank test for in-hospital mortality.
Reference group: no-HTS. Adjusted for age, initial National Institutes of Health Stroke Scale score, pre-stroke modified Rankin Scale score, previous antiplatelet treatment, reperfusion therapy, and TOAST classification. OR: odds ratio; HR: hazard ratio; LOS: hospital length of stay; TOAST: Trial of Org 10172 in Acute Stroke Treatment. Length of stay was log-transformed prior to analysis; β represents the difference in log-transformed days between groups.
Crude odds ratios were estimated using logistic regression with no-HTS as the reference group. Adjusted odds ratios were derived from multivariable logistic regression adjusting for age, initial NIHSS score, pre-stroke modified Rankin Scale score, previous antiplatelet treatment, reperfusion therapy (none/IVT/EVT/IVT+EVT), and TOAST classification. The crude P for trend was calculated using the Cochran-Armitage trend test. The adjusted P for trend was obtained by including HTS frequency as an ordinal variable (0, 1, 2, ≥3) in the multivariable logistic regression model. OR: odds ratio; HTS: hypertonic saline; NIHSS: National Institutes of Health Stroke Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment.
Multivariable logistic regression model with phlebitis as the dependent variable. All listed covariates were entered simultaneously. Hypertonic saline use was the primary exposure variable. OR: odds ratio; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; IVT: intravenous thrombolysis; EVT: endovascular treatment; TOAST: Trial of Org 10172 in Acute Stroke Treatment.